Differential gene expression analysis related to extracellular matrix components in drug-resistant RPMI-8226 cell line

Biomedicine and Pharmacotherapy

Volumn 66, Issue 3, 2012, Pages 228-231

  Mutlu, Pelin ^a   Ural, Ali Ugur ^b   Gündüz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

CDNA microarray; Drug resistance; Extracellular matrix

Indexed keywords

ALPHA INTEGRIN; ALPHA5 INTEGRIN; ALPHA6 INTEGRIN; BETA2 INTEGRIN; COLLAGEN TYPE 11; COLLAGEN TYPE 18; COLLAGEN TYPE 4; COLLAGEN TYPE 7; COLLAGEN TYPE 8; COLLAGEN TYPE 9; FIBRONECTIN; LAMININ GAMMA1; MELPHALAN; PREDNISONE; VINCRISTINE;

ARTICLE; BLOOD VESSEL WALL; DOWN REGULATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; UPREGULATION;

ADAM PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; MELPHALAN; MULTIPLE MYELOMA; PREDNISONE; TUMOR MICROENVIRONMENT; UP-REGULATION; VINCRISTINE;

EID: 84860242490     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.11.023     Document Type: Article

References (24)

1. Klappe K., Hinrichs J.W., Kroesen B.J., Sietsma H., Kok J.W. MRP1 and glycosylceramide are coordinately overexpressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer 2004, 110:511-522.
2. Dalton W.S. The tumor microenvironment: focus on myeloma cancer. Cancer Treat Rev 2003, 29:11-19.
3. Yang H.H., Ma M.H., Vescio R.A., Berenson J.R. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003, 21:4239-4247.
4. Lisenmeyer M.E., Jeferson S., Wolf M., Matthews J.P., Board P.G., Woodcock D.M. Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer 1992, 65:471-475.
5. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004, 4:528-539.
6. Shain K.H., Landowski T.H., Dalton W.S. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo resistance. Curr Opin Oncol 2000, 12:557-563.
7. Sethi T., Rintoul R.C., Moore S.M., Mackinnon A.C., Salter D., Choo C., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999, 5:662-668.
8. Dalton W.S. Drug resistance and drug development in multiple myeloma. Semin Oncol 2002, 29:21-25.
9. Hoyt D.G., Rusnak J.M., Mannix R.J., Modzelewski R.A., Johnson C.S., Lazo J.S. Integrin activation suppresses etoposide induced DNA strand breakage in cultured murine tumor-derived endothelial cells. Cancer Res 1996, 56:4146-4149.
10. Kraus A.C., Ferber I., Bachmann S.O., Specht H., Wimmel A., Gross M.W., et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002, 21:8683-8695.
11. Morin P.J. Drug resistance and microenvironment: nature and nurture. Drug Resist Update 2003, 6:169-172.
12. Liang Y., Meleady P., Cleary I., MacDannell S., Connally L., Clynes M. Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer 2001, 37:1041-1052.
13. Robert C.R., Tariq S. The role of extracellular matrix in small-cell lung cancer. Lancet Oncol 2001, 2:437-442.
14. Humphries M.J. Integrin structure. Biochem Soc T 2000, 28:311-339.
15. Ahmed N., Riley C., Rice G., Quinn M. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin Exp Metastasis 2005, 22:391-402.
16. Shain K.Y., Yarde D.N., Meads M.B., Huang M., Jove R., Hazlehurst L.A., et al. Beta 1 integrin adhesion enhances IL-6 mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009, 69:1009-1015.
17. Liang Y., Meleady P., Cleary I., McDonnell S., Connolly L., Clynes M. Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer 2001, 37:1041-1052.
18. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-1667.
19. Carinci F., Piattelli A., Guida L., Perrotti V., Laino G., Oliva A., et al. Effects of emdogain on osteoblast gene expression. Oral Dis 2006, 12:329-342.
20. Yang L., Froio R.M., Sciuto T.E., Duorak A.M., Alon R., Luscinskas F.W. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 2005, 106:584-592.
21. Bentan G., Crooke E., George J. Laminin-1 induces E-cadherin expression in 3-dimensional cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status. FASEB J 2009, 23:3884-3895.
22. Chou M.Y., Li H.C. Genomic organization and characterization of human type XXI collagen (COL21A1) gene. Genomics 2002, 79:395-401.
23. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C.R., et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 2001, 98:1024-1029.
24. Edwards D.R., Handsley M.M., Pennigton C.J. The ADAM metalloproteinases. Mol Aspects Med 2008, 29:258-289.